Edesa Biotech (EDSA) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed ProMIS Neurosciences (PMN) over the past year, gaining 17.6% versus a loss of 69.9%. Over five years, EDSA leads with a -95.6% price change compared with -98.2% for PMN. ProMIS Neurosciences is the larger company by market cap ($28.4 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | PMN |
|---|---|---|
| Share price | $2.00 | $3.16 |
| Market cap | $27.02M | $28.43M |
| 1-day change | -8.05% | -1.56% |
| YTD return | +40.85% | -53.73% |
| 1-year return | +17.65% | -69.90% |
| 5-year return | -95.63% | -98.24% |
| EPS (TTM) | $-1.72 | $-6.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.19M | $-39.72M |
| 52-week high | $20.32 | $27.40 |
| 52-week low | $0.72 | $2.78 |
| Distance from 52-week high | -90.16% | -88.47% |
| Analyst consensus | none | none |
| Avg. price target upside | +716.50% | +1248.42% |
| Average volume | 1.45M | 164.88K |
| Shares outstanding | 13.51M | 9.00M |
| Employees | 17 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed PMN by 87.6 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
EDSA vs PMN FAQ
Which is bigger, Edesa Biotech or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $28.43M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or PMN?
EDSA returned +17.65% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.